These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Case report: Preventive infusion of donor-derived CD7 chimeric antigen receptor T cells after allogeneic hematopoietic stem cell transplantation. Jiang Y; Feng D; Zhu J; Wei D; Zhao C; Liu H; Shao S; Wang C Front Immunol; 2024; 15():1381308. PubMed ID: 38745670 [TBL] [Abstract][Full Text] [Related]
5. A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T-cell therapy. Cao XY; Zhang JP; Lu Y; Zhao YL; Liu DY; Xiong M; Sun RJ; Wei ZJ; Zhou JR; Zhang X; Yang JF; Li J; Lu P Br J Haematol; 2024 Jun; 204(6):2351-2364. PubMed ID: 38613241 [TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia. Xie L; Ma L; Liu S; Chang L; Wen F Int Immunopharmacol; 2021 Jul; 96():107731. PubMed ID: 33965880 [TBL] [Abstract][Full Text] [Related]
7. Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-based CRS Management. Li S; Wang X; Yuan Z; Liu L; Luo L; Li Y; Wu K; Liu J; Yang C; Li Z; Wang D; Shen L; Ye X; He J; Han C; Wang Y; Zhang D; Dong Y; Fang L; Chen Y; Sersch M; Cao WW; Wang S Clin Cancer Res; 2021 Mar; 27(5):1242-1246. PubMed ID: 33234511 [TBL] [Abstract][Full Text] [Related]
8. Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis. Hu Y; Zhang M; Yang T; Mo Z; Wei G; Jing R; Zhao H; Chen R; Zu C; Gu T; Xiao P; Hong R; Feng J; Fu S; Kong D; Xu H; Cui J; Huang S; Liang B; Yuan X; Cui Q; Guo H; Yu Y; Feng Y; Jin C; Ren J; Chang AH; Wang D; Huang H N Engl J Med; 2024 Apr; 390(16):1467-1480. PubMed ID: 38657244 [TBL] [Abstract][Full Text] [Related]
9. Donor CD7 Chimeric Antigen Receptor T Cell Bridging to Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Hematologic Malignancy. Li Z; An N; Yang K; Meng F; Xu T; Peng X; Wen X; Li J; Song Y; Yang R; Wu T Transplant Cell Ther; 2023 Mar; 29(3):167-173. PubMed ID: 36427783 [TBL] [Abstract][Full Text] [Related]
10. Case report: Two pediatric cases of long-term leukemia-free survival with relapsed acute T-lymphoblastic leukemia treated with donor CD7 CAR-T cells bridging to haploidentical stem cell transplantation. Song Y; Liu Z; Wang Q; Gao K; Wu T Front Immunol; 2024; 15():1333037. PubMed ID: 38481998 [TBL] [Abstract][Full Text] [Related]
11. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Benjamin R; Graham C; Yallop D; Jozwik A; Mirci-Danicar OC; Lucchini G; Pinner D; Jain N; Kantarjian H; Boissel N; Maus MV; Frigault MJ; Baruchel A; Mohty M; Gianella-Borradori A; Binlich F; Balandraud S; Vitry F; Thomas E; Philippe A; Fouliard S; Dupouy S; Marchiq I; Almena-Carrasco M; Ferry N; Arnould S; Konto C; Veys P; Qasim W; Lancet; 2020 Dec; 396(10266):1885-1894. PubMed ID: 33308471 [TBL] [Abstract][Full Text] [Related]
12. Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Zhang Y; Li C; Du M; Jiang H; Luo W; Tang L; Kang Y; Xu J; Wu Z; Wang X; Huang Z; Zhang Y; Wu D; Chang AH; Hu Y; Mei H Blood Cancer J; 2023 Apr; 13(1):61. PubMed ID: 37095094 [TBL] [Abstract][Full Text] [Related]
13. Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy. Chen W; Shi H; Liu Z; Yang F; Liu J; Zhang L; Wu Y; Xia Y; Ou Y; Li R; Zhang T; Zhang J; Ke X; Hu K; Yu J Clin Cancer Res; 2023 Apr; 29(8):1484-1495. PubMed ID: 36735547 [TBL] [Abstract][Full Text] [Related]
14. Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma. Zhang M; Chen D; Fu X; Meng H; Nan F; Sun Z; Yu H; Zhang L; Li L; Li X; Wang X; Wang M; You F; Li Z; Chang Y; Zhou Z; Yan J; Li J; Wu X; Wang Y; Wang Y; Xiang S; Chen Y; Pan G; Xu H; Zhang B; Yang L Clin Cancer Res; 2022 Jul; 28(13):2830-2843. PubMed ID: 35435984 [TBL] [Abstract][Full Text] [Related]
15. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. Hu Y; Zhou Y; Zhang M; Zhao H; Wei G; Ge W; Cui Q; Mu Q; Chen G; Han L; Guo T; Cui J; Jiang X; Zheng X; Yu S; Li X; Zhang X; Chen M; Li X; Gao M; Wang K; Zu C; Zhang H; He X; Wang Y; Wang D; Ren J; Huang H Cell Res; 2022 Nov; 32(11):995-1007. PubMed ID: 36151216 [TBL] [Abstract][Full Text] [Related]
16. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas. Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y Front Immunol; 2020; 11():564099. PubMed ID: 33329526 [TBL] [Abstract][Full Text] [Related]
17. Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission. Miao X; Shuai Y; Han Y; Zhang N; Liu Y; Yao H; Wang X; He G; Chen D; Fan F; Chang AH; Su Y; Yi H Front Immunol; 2024; 15():1389227. PubMed ID: 38803489 [TBL] [Abstract][Full Text] [Related]
18. Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy. Zhang X; Yang J; Li J; Qiu L; Zhang J; Lu Y; Zhao YL; Jin D; Li J; Lu P Am J Hematol; 2023 Dec; 98(12):1898-1908. PubMed ID: 37740926 [TBL] [Abstract][Full Text] [Related]
19. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. Chen Y; Cheng Y; Suo P; Yan C; Wang Y; Chen Y; Han W; Xu L; Zhang X; Liu K; Chang L; Xiao L; Huang X Br J Haematol; 2017 Nov; 179(4):598-605. PubMed ID: 29076142 [TBL] [Abstract][Full Text] [Related]